Loading...
Market
What will be the main outcome of Ozempic trials for Alzheimer's by 2025?
2
Resolution / Starting Odds
Highly effective • 25%
Moderately effective • 25%
Slightly effective • 25%
Not effective • 25%
Published results in peer-reviewed scientific journals or official announcements from research institutions
Story
Ozempic Shows Promise in Reducing Advanced Alzheimer's Risk, Potential 70% Reduction in Dementia by 2025
Dec 26, 2024, 08:53 AM
Recent studies are exploring the potential of Ozempic, a weight-loss medication, to aid in the fight against advanced Alzheimer's disease. Scientists are investigating its anti-inflammatory properties, which may contribute to a significant reduction in the risk of developing dementia. Early findings indicate that patients receiving the medication could see up to a 70% reduced risk of dementia. However, further research is needed, with more comprehensive results expected in 2025.
View original story
Similar markets
No decision made • 25%
No distribution approved • 25%
Approve limited distribution • 25%
Approve distribution city-wide • 25%
Safety label update • 25%
Product recall • 25%
No action taken • 25%
Other regulatory actions • 25%
Inconclusive results • 25%
Confirms significant risk • 25%
Study retracted • 25%
No significant risk found • 25%
No publication • 25%
Confirms link • 25%
Refutes link • 25%
Inconclusive • 25%
No campaigns • 25%
By Novo Nordisk • 25%
By health organizations • 25%
By both • 25%
Falls short of expectations • 25%
Trial cancelled • 25%
Meets expectations • 25%
Exceeds expectations • 25%
Yes • 50%
No • 50%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Negative efficacy, but good safety • 25%
Positive efficacy, but safety concerns • 25%